CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes

PURPOSE. No effective therapy is available for unresectable soft tissue sarcomas (STS). This unmet clinical need has prompted us to test whether chondroitin sulfate proteoglycan 4 (CSPG4)-specific CAR-redirected cytokine-induced killer lymphocytes (CAR.CIK) are effective in eliminating tumor cells d...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Leuci, Valeria, Donini, Chiara, Grignani, Giovanni, Rotolo, Ramona, Mesiano, Giulia, Fiorino, Erika, Gammaitoni, Loretta, D’Ambrosio, Lorenzo, Merlini, Alessandra, Landoni, Elisa, Medico, Enzo, Capellero, Sonia, Giraudo, Lidia, Cattaneo, Giulia, Iaia, Ilenia, Pignochino, Ymera, Basiricò, Marco, Vigna, Elisa, Pisacane, Alberto, Fagioli, Franca, Ferrone, Soldano, Aglietta, Massimo, Dotti, Gianpietro, Sangiolo, Dario
Format: Artigo
Language:Inglês
Published: 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7710537/
https://ncbi.nlm.nih.gov/pubmed/32900797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-0357
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items